Physician profile
Patrick W Gray
NPI 1942208855
$845.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $145 · 2021: $286 · 2022: $206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $180.49 | 2019-2022 | |
| Novo Nordisk INC | $154.51 | 2019-2021 | |
| Lilly USA, LLC | $102.75 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $70.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $54.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $51.89 | 2021-2022 | |
| Amgen INC. | $37.53 | 2019 | |
| Abbott Laboratories | $36.72 | 2022 | |
| Dexcom, INC. | $20.68 | 2021 | |
| Horizon Therapeutics Plc | $20.35 | 2019 | |
| Astellas Pharma US INC | $20.07 | 2022 | |
| Mylan Specialty L.P. | $16.75 | 2019 | |
| Eisai INC. | $14.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2022 | |
| Merck Sharp & Dohme LLC | $13.45 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.11 | 2022 | |
| Medtronic USA, INC. | $12.31 | 2019 | |
| Biogen, INC. | $11.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.